Overview

Drug discovery aims to find and develop molecules that act on disease-relevant targets or biological processes, while balancing efficacy, safety, and the ability to make them. AI methods include graph and 3D models for predicting molecular properties, binding, and toxicity; generative models for proposing or editing molecules; and knowledge graphs and omics models for prioritizing targets and interpreting biological responses. Search and design methods increasingly combine these predictions with docking, synthesis constraints, experimental data, and tools coordinated by AI agents. A central challenge is that strong results on standard benchmarks may not transfer to unseen targets, chemistry, or assays, and computational scores still need reliable experimental validation.

Latest papers

178 papers15 papers in the last four weeks, down 37% on the four weeks before. 0.1% of all new papers.

Nov 15, 2026

Reasoning in the loop: antibody lead optimization by probing mechanism and measurement

Lab-in-the-loop systems, in which a model proposes molecules, automated assays measure their properties and the results retrain the model, are a popular approach to antibody lead optimization. These systems optimize for a specification defined with metrics computed from instrument signals, so their success depends on how well those metrics serve as proxies for the properties a drug candidate needs. When a metric is a poor proxy, neither a better model nor more data will fix it, and identifying the problem usually requires expert review. We report two campaigns run on BigHat Biosciences' Milliner platform, one on an anti-albumin nanobody (VHH) and one on an anti-mesothelin single-chain variable fragment (scFv), in which a research team and a general-purpose AI agent, Claude, brought scientific reasoning into the loop. Over seven rounds and about 1,010 design variants we built libraries from antibody lineage, structure and biophysics, and found from the raw curves that on each scaffold one thermal metric did not measure what its name implied. The libraries were built as controlled comparisons, so the results also show what each mutation contributes to each property. We fit a physical model of the curves, used it to choose metrics suited to each scaffold, and changed the experimental protocol, varying protein concentration and heating rate, to test the model against pre-registered predictions. Both leads improve on their parents in affinity, thermal stability and aggregation while improving or maintaining yield and purity.
Nov 12, 2026

Using an energy pixels approach to estimate the size a 2nd Generation DEL must be to train a high-resolution binding model

DNA-encoded libraries (DELs) are commonly used to find small-molecule binders to a target protein. But the hard part is no longer finding a hit. It is building a machine-learning model good enough to guide the medicinal chemistry that follows, one that can resolve the shift in affinity when a chemist changes a single atom. Such a model needs two things from its training data: dense sampling of the small patch of chemical space around the hit, and an adequate number of genuinely tight binders within it. A diverse naive DEL gives neither. It samples an enormous space, so any one neighborhood is covered far too thinly, and the tightest binders are rare. A model trained on that naive DEL data must extrapolate to binders tighter than any it has seen, and that is where models can fail. One way to get training data with both properties is a second-generation DEL built around the hit. We ask how complex that library must be. We treat binding as a sum of small, independent interactions, called pixels on the target and antipixels on the ligand. From the spread of affinities measured in the naive library, with no structural information and nothing yet synthesized, we estimate the complexity such a library must have to supply that dense sampling and those tight binders. The method does two useful things. It turns the number of tight binders a model needs into the number of compounds a library must contain. And it estimates the expected yield of a randomly designed second-generation DEL, so the gain from designing the library with machine learning or active learning can be measured against a baseline, without the expense of a control library as large as the experiment itself.
Nov 11, 2026

CupOFMoCA: Coupled Objective-Guided Discrete Flows for Molecular Conjugate Assembly

Molecular conjugates, including PROTACs and peptide-drug conjugates (PDCs), derive their function from the joint behavior of multiple coupled components, yet most generative approaches design these components independently and combine them only after generation. Such staged pipelines ignore cross-component dependencies and often produce conjugates that are chemically invalid, fall outside empirical conjugate distributions, or lose function upon assembly. In this work, we introduce Coupled Objective-Guided Discrete Flows for Molecular Conjugate Assembly (CupOFMoCA), a discrete generative method that enforces cross-component chemical constraints during conjugate generation. CupOFMoCA restricts guided updates to chemically feasible conjugate states and reweights local transitions using molecular design objectives. Across three PDC systems, coupled generation achieved 100% conjugation validity among valid peptides and increased valid yield over matched post-hoc filtering, with comparable predicted binding scores across the full valid sets. In three-seed evaluations of three PROTAC systems, CupOFMoCA achieved the highest assembly validity on two systems and generated more assembly-valid molecules per second than the evaluated baselines. We further evaluated the generated PROTACs with post-hoc DegradeMaster scoring and explicit-solvent molecular dynamics, supporting their predicted activity and conformational properties. Together, these results establish CupOFMoCA as an efficient generator of molecular conjugates, supporting therapeutic development via coordinated control of assembly and molecular properties.
Nov 10, 2026

DrugCoding: A Scientific Programming Agent for Drug Discovery

Drug discovery involves multiple interconnected research stages, including molecular design, property prediction, and virtual screening. These processes are characterized by complex workflows, interdependent computational tasks, and diverse specialized tools, placing substantial demands on the coordination of scientific models and computational resources. However, existing large language model (LLM)-based scientific agents still face challenges in autonomous planning of complex tasks, adaptive selection of specialized models, and reliable execution of multi-stage scientific computations, limiting their effectiveness in automating complex drug discovery workflows. To address these challenges, we propose DrugCoding, a scientific programming agent system that integrates scientific task planning, adaptive model routing, multi-agent collaboration, and programmatic tool execution. DrugCoding enables autonomous task planning and dynamic model adaptation for complex research objectives. It can flexibly invoke specialized scientific models, autonomously generate and execute code according to task requirements, and leverage multi-agent collaboration to support efficient execution and reliable validation of complex scientific tasks. To evaluate DrugCoding's performance in scientific tool invocation and multi-stage task execution, we conduct multi-turn tool-calling experiments across diverse language models and scientific tool interfaces. Experimental results demonstrate that DrugCoding achieves an average session-level Pass@1 of 97.35% on the full benchmark, outperforming the strongest baseline, Codex, by 9.24%. On the challenging subset, DrugCoding achieves 97.92%, exceeding the strongest baseline.
Nov 10, 2026

The Dose Makes the Poison: Exposure-Aware Evaluation of Generative Drug Design

Generative models are increasingly used to propose molecules for drug discovery. They can produce far more candidates than can be experimentally tested, making computational selection essential. Most selection methods rely on predicted molecular properties, such as potency and toxicity, but overlook how these properties translate into drug exposure at a given dose. As a result, molecules that appear promising on paper may require impractical doses or raise safety concerns. We investigate this gap by using physiologically based pharmacokinetic (PBPK) simulations to re-evaluate molecules selected from three PARP1-targeted generative pipelines. Of 60 shortlisted molecules, seven fail to achieve sufficient target exposure, while 28% of the remaining candidates show predicted safety risks at their required dose. Moreover, 85% of candidates with an achievable dose are outperformed by molecules overlooked during static selection. These findings suggest that accounting for dose and exposure can substantially change which generated molecules are considered promising for drug development.
Nov 5, 2026

PharmAgents2: Towards Autonomous End-to-End Drug Discovery

Drug discovery requires continuous scientific decision-making across a vast research space. We introduce PharmAgents2, an autonomous system for end-to-end drug discovery that combines knowledge-enhanced decision-making with organized large-scale exploration. Paper2Skill extracts transferable scientific decision knowledge from public sources and, together with expert-developed skills, supports research decisions. Self-Scaling Discovery expands exploration through parallel agents inheriting research context and decision-making capabilities across targets, scientific hypotheses, and discovery strategies. We introduce PharmAgents-Bench v0.1, comprising 121 questions across nine decision scenarios and three end-to-end tasks assessed with expert-defined process rubrics. PharmAgents2 outperforms evaluated baselines in most decision categories and achieves the highest process scores on all three end-to-end tasks. In three real-world studies, autonomous investigations generated findings subsequently supported by human-executed experiments. For LpxH, PharmAgents2 hypothesized a previously unreported allosteric site and screened compounds against it, identifying a novel inhibitor scaffold with experimentally confirmed inhibitory activity and binding. For JAK1, it prioritized a covalent inhibition strategy and nominated compounds with experimentally demonstrated activity. Starting from a known bioactive molecule, Self-Scaling Discovery explored candidate targets across the proteome and identified a new binding target, with the interaction subsequently confirmed experimentally. PharmAgents2 represents a prototype of a virtual pharmaceutical company, marking a step toward autonomous end-to-end drug discovery.
Nov 2, 2026

El Agente Fármaco: A Scalable AI Scientist for Drug Discovery

Computational drug discovery offers a growing range of tools for proposing and evaluating molecules, but combining them and deciding what to do next still requires substantial expert effort. Here, we introduce El Agente Fármaco, an AI scientist that uses modern large language model (LLM) technology to turn discovery goals expressed in everyday language into complex, scalable computational screening workflows. The agentic harness selects scientific tools, reviews their results, and adjusts subsequent steps to the target and the user's objectives. Our approach centers on a shared scientific memory: Fármaco Atlas, which stores molecules, structures, and results together with their provenance -- a record of how they were obtained. The agent uses targeted database queries to retrieve the evidence needed for each decision. A single request can launch calculations for an entire collection of molecules, without requiring a separate LLM decision for every compound. This design limits the information the model must process as screening collections grow, while keeping the underlying results available for inspection and further analysis. The integrated tools support molecule generation, prediction of binding and molecular properties, and searches for compounds available for purchase. In a retrospective comparison with an expert-led campaign, the agent proposed chemically distinct candidates with competitive docking scores and higher calculated drug-likeness under explicitly imposed selection criteria. In a 22-task benchmark against plain tool calls and Codex, the agent achieved the highest observed mean model-judged score, with lower median cumulative token use and peak context. Fármaco provides a foundation for flexible, scalable drug discovery workflows that connect scientific reasoning with an enduring, traceable record of computational work.
Oct 31, 2026

Can agents reliably design therapeutic antibodies?

Recent work has demonstrated agents driving protein design workflows, either through orchestration of specialized tools or direct manipulation of sequences. Yet the fidelity with which agents follow protein design instructions and the factors contributing to their effectiveness remain understudied. We examine agentic antibody design under two settings: when explicit molecular-editing instructions are provided and when agents receive only previously-scored sequences and are prompted to propose improvements. We call the first task-guided and the second black-box design. For the task-guided setting, we curate ten expert-validated affinity-improvement tasks and show that LLM judges closely reproduce programmatic evaluations of instruction following. We then study two augmentations: access to antibody-relevant tools and to previously scored design history. Tools improve instruction following (IF) and sequence space exploration while reducing optimization performance, whereas design history reduces IF but improves optimization performance at the expense of exploration. Finally, we combine taskguided and black-box design within an in silico optimization loop and show that our agentic optimizer performs comparably to an established Bayesian optimization baseline.
Oct 30, 2026

DELBERT-2: Pretrained Fingerprint Language Models for DEL Protein Binder Prediction

We present DELBERT-2, a pretrained fingerprint language model that converts sparse molecular fingerprints into unified token sequences using a ModernBERT encoder trained with masked language modelling on 2.5M molecules from the AIRCHECK DEL corpus. We evaluate across six targets (WDR91, WDR12, SETDB1, PLCZ1, LRRK2, DCAF7) under three out-of-distribution (OOD) protocols: hierarchical cluster splits probe chemical novelty, library splits test cross-library transfer, and building-block splits assess compositional generalization. DELBERT-2 consistently improves PR-AUC and NDCG@1000 relative to LightGBM ensemble baselines and transformers trained from scratch, with the largest gains in stringent OOD regimes. DELBERT-2 achieves 13.28+/-3.72 enrichment factor at top-100 vs. 12.36+/-3.75 for no-pretraining (p=0.040), representing 7.4% improvement and 13x enrichment over random selection. These results demonstrate that fingerprint-centric self-supervised learning effectively improves hit prioritization under distribution shift, enabling practical DEL virtual screening. Code is available at \hyperlink{https://github.com/GenerativeDrugDiscovery/DELBERT-2}{DELBERT-2}.
Oct 30, 2026

Transferring Peptide-Target Interaction Patterns to Small Molecules by Joint Guidance for Diffusion and Flow Matching

Generating small molecules to target protein-protein interactions (PPIs) remains one of the most challenging yet high-reward frontiers in drug discovery. Unlike traditional small-molecule drugs that bind to deep, well-defined pockets, PPI interfaces often comprise broad, shallow binding surfaces. A natural strategy is to leverage known peptide-target interactions, as peptide ligands provide rich interface-level constraints. However, a major algorithmic challenge is that rigid atom-level conditioning on peptide structures can over-constrain the generative space and exclude valid small-molecule solutions. To address this challenge, we present PIFT (Peptide InterFace Transfer), a novel framework that transfers peptide-target interaction patterns to small molecules through joint sampling-time guidance of masked discrete diffusion and continuous flow matching. PIFT first maps peptide-target and small-molecule-target interfaces into a shared, target-conditioned interaction space, capturing transferable interface information across molecular modalities. The resulting peptide-derived reference then jointly steers building-block logits and 3D coordinates toward peptide-compatible molecules while preserving a strong adapted molecular prior. Extensive experiments across diverse PPI targets show that the learned representation captures cross-modal interaction compatibility, while peptide guidance improves interface recovery and achieves strong docking performance and favorable molecular properties.
Oct 29, 2026

D2ML: Models for Direct-to-Biology Small Molecule Screening

Direct-to-biology (D2B) screening enables rapid testing of newly synthesized molecules without purification. However, uncertain concentrations in crude mixtures and limited purified-compound measurements complicate the use of these data in machine learning. Here we show that models tailored to the structure of D2B data can improve prediction and guide the discovery of more potent and selective compounds. Our assay-aware models predict activity from single-point screens, relative potency across targets from crude dose-response assays, and absolute potency from purified-compound measurements. For crude assays, potency ratios between targets tested from the same well can retain selectivity information despite uncertain concentrations. A joint model that shares information across stages and balances their contributions to training improved predictions over separate neural networks. The largest gain was in crude dose-response selectivity prediction, where rank correlation increased from 0.27 to 0.40. In a separate experiment, independently trained models guided the selection of 84 new compounds to improve ROS1 potency while limiting activity against the anti-target TRKB. Synthesis and testing identified compounds that extended the measured Pareto front, achieving better combinations of potency and selectivity than those in the training data. The most selective new compound achieved a ROS1 IC50 of 14.7 nM and 233-fold selectivity over TRKB. By comparison, the most selective training compound had a ROS1 IC50 of 20.3 nM and 79-fold selectivity. ATLAS provides the experimental setting for this approach, supporting synthesis and screening of 1,000-10,000 model-selected compounds in two- to three-week cycles. Together, these results show how assay-aware learning can use the full D2B assay sequence to guide multi-objective molecular optimization.
Oct 29, 2026

MoLRSI: A Recursive Self-Improving AI agent for Molecular Discovery

Molecular discovery requires navigating vast combinatorial search spaces while balancing competing biological objectives. AI agents can automate expert-defined molecular design protocols, but automation alone does not address how to optimize workflows for new tasks or improve their development through experience. Here we introduce MoLRSI, an AI agent that combines systematic optimization of workflows and model architectures with persistent cross-task memory to recursively improve its search policy for molecular discovery. Workflow performance, refinement outcomes, and execution feedback guide subsequent searches, allowing the agent to improve both its workflows and its strategy for developing them. We evaluate MoLRSI in two challenging molecular discovery settings that require balancing competing properties. In antibiotic discovery, MoLRSI developed a screening workflow balancing antibacterial activity, cytotoxicity and structural novelty, achieving an experimental hit rate of 15.9%, compared with 8.7% for a previous expert-led workflow using the same training data and screening library. In de novo peptide-MHC binder design, MoLRSI developed workflows that jointly consider target binding and specificity, producing eight experimentally validated hits against MART-1 and SARS-CoV-1 pMHCs with preferential binding over tested off-targets while Claude Science completely failed. These findings demonstrate how experience-guided workflow optimization can address competing discovery objectives while improving the search strategies used in subsequent campaigns.
Oct 23, 2026

Computational De Novo Design of Miniprotein Candidate Neutralizers Targeting the IL-23 Cytokine Subunit p19

Interleukin-23 (IL-23) drives T-helper-17 inflammation underlying inflammatory bowel disease and psoriasis; anti-p19 antibodies are clinically effective but large, costly, and injectable. De novo miniproteins are an attractive alternative, yet published designs target the IL-23 receptor; the IL-23 cytokine itself has not been addressed. A further obstacle is that the standard confidence score (ipTM) tracks construct length rather than interface quality. We computationally design miniprotein binders against the IL-23R-binding face of p19 (PDB 3DUH) and score every design with ipSAE, a length-robust interface metric derived from AlphaFold-initial-guess predicted aligned error. A conventional RFdiffusion/ProteinMPNN/ColabFold pipeline yields no reliable predicted interface across 972 designs (best ipSAE 0.30), and a scoring artifact, in which single-sequence ColabFold under-rates binder pLDDT by approximately 56 points, explains an earlier misleading "binders do not fold" signal. An interface-optimized hallucination method (BindCraft), scored identically, yields 42 of 50 designs above ipSAE 0.60 (best 0.804). An AlphaFold-independent geometric check reproduces the conventional failure: no top-ranked conventional design reaches the buried area or interface hydrogen-bond count of the weakest lead. Five all-alpha-helical leads (72-104 residues) collectively engage all six targeted hotspots; two dock within the intact p40/p19 heterodimer and all show favorable Rosetta energetics. A p40-alone counter-screen returns ipSAE 0.00 for all five, indicating no spurious p40 interface. To our knowledge, these are the first computationally proposed de novo miniprotein candidates designed to occlude the IL-23R-binding face of IL-23 p19. All results require experimental validation.
Oct 23, 2026

A curated multi-endpoint drug-protein bioactivity dataset with construct-aware protein targets

Public drug-protein bioactivity resources commonly identify targets by UniProt accession, although one accession may represent distinct experimental sequences. We present Curate-DTI, a construct-aware dataset derived from the 1 July 2026 BindingDB export, with IC50, Ki, Kd and EC50 processed independently. The release contains 2,919,717 measurements, 1,291,872 standardized ligands, 9,668 sequence-defined protein entities and 2,275,683 endpoint-specific interactions spanning 8,336 reviewed UniProt accessions. Protein entities combine the accession with the reported experimental sequence, preserving constructs that accession-only processing would merge. Across the four endpoints, 4,204 endpoint-specific ligand-accession groups showed different classification labels across sequence-defined protein entities. Exact and inequality-qualified observations provide relation-aware classification evidence, whereas regression targets use exact values only. Connected Parquet tables preserve individual measurements, standardized structures, protein sequences, aggregated interactions and available assay and source provenance. The resource supports endpoint-specific classification and regression while allowing users to select molecular representations, protein representations and evaluation splits. Preprocessing code, a column dictionary, exclusion reports and validation summaries accompany the release.
Oct 19, 2026

HierDTA: Hierarchical Structure-Aware Representation Learning for Drug--Target Affinity Prediction

Drug--target affinity (DTA) prediction plays an important role in computer-aided drug discovery, where reliable computational models can help prioritize compound--protein pairs before experimental validation. A key challenge in DTA prediction is to effectively mine multi-level molecular information from drug structures while accurately modeling the binding-site environment of target proteins. To address these issues, we introduce HierDTA, a hierarchical structure-aware framework for DTA prediction. \textcolor{black}{HierDTA represents each drug as an atom--motif heterogeneous graph and introduces an augmentation module that propagates functional-motif semantics to the corresponding atoms. For proteins, kinase-domain structures are converted into residue interaction graphs. The resulting atom and residue representations are integrated using cross-attention to capture pair-specific relationships, while molecule fingerprints and pretrained ESM-2 embeddings provide complementary global information. Compared with state-of-the-art methods, HierDTA achieves superior performance on the Davis dataset across all metrics and attains the highest rm2r_m^2 of 0.791 on KIBA. It also exhibits strong generalization under cold-start settings, particularly on KIBA, where MSE is reduced by 21.7% in the unseen-protein scenario. Ablation study and interpretability analysis supported the contributions of the hierarchical augmentation and interaction components.} Case studies further showed that HierDTA provided early enrichment of candidate bioactive compounds. These results indicate that HierDTA is an effective framework for affinity prediction and target-specific virtual screening.
Oct 17, 2026

Generative Retrieval for Reverse Target Fishing with a Proteome-Scale Benchmark

Reverse target fishing identifies protein targets for a query molecule and is central to drug discovery and repurposing. Discriminative approaches adapted from virtual screening face sparse, long-tailed associations and missing-not-at-random measurements: treating unrecorded pairs as negatives can suppress genuine targets. We reformulate the task as generative retrieval and introduce GenFish. Residual vector quantization converts frozen protein language model features into shared semantic identifiers. Given a molecular fingerprint, GenFish autoregressively models codes conditioned on the query and preceding code, ranking proteins by identifier likelihood without explicitly labeling unrecorded pairs as negatives. We introduce ProTargetBench, the first proteome-scale benchmark for reverse target fishing to jointly support measured-panel discrimination and full-catalogue recovery of experimentally recorded positives. Covering 20,431 UniProt-reviewed human proteins, it integrates curated bioactivity evidence and distinguishes experimental inactivity from unmeasured associations. On 198 held-out molecules, GenFish achieves higher mean performance across all three full-catalogue retrieval metrics than four discriminative neural baselines and three non-neural baselines, including ligand-based methods. A controlled positive-hiding experiment shows that targeted removal of false-negative competition improves contrastive retrieval beyond matched random masking; GenFish remains stronger under the same incomplete supervision. Pfam alignment indicates that the semantic identifiers capture biologically meaningful relationships among proteins. These results establish generative retrieval as a principled paradigm for reverse target fishing under incomplete bioactivity records.
Oct 16, 2026

On the Selectivity of Generative Models in Structure-Based Drug Design

Designing small-molecule drugs that selectively bind to a target protein while avoiding unintended interactions with other proteins is essential for reducing side effects that contribute substantially to clinical attrition. Although structure-based drug design (SBDD) has advanced rapidly with deep learning, most generative models still optimize binding to a single target and disregard selectivity due to limited training data and unknown off-target interactions. Motivated by this gap, we introduce SELECTBENCH, a comprehensive benchmark assessing the selectivity of generative SBDD models. SELECTBENCH provides three curated evaluation tasks reflecting different real-world drug discovery scenarios: literature-based case studies, safety screening panels used in pharmaceutical development, and large-scale structure-based evaluation sets. We further introduce a suite of metrics to quantify selectivity and conduct a systematic evaluation of nine representative SBDD models, including methods explicitly trained for selectivity and widely-used inference-time guidance techniques. Our results show that even selectivity-trained models achieve only modest off-target discrimination and inference-time guidance provides limited gains, underscoring the need for method improvement. SELECTBENCH provides both a characterization of where current generative SBDD stands on selectivity and an open, extensible platform to accelerate progress. The benchmark is available at https://github.com/lovetaro/selectbench.
Oct 16, 2026

DrugHarness: An Evolvable Agent Harness for Computational Drug Discovery

Computational drug discovery requires agents to compose scientific operations and adapt to changing evidence and constraints. Here we introduce DrugHarness, an evolvable agent harness coupling composable scientific execution with conditional skill induction. Its environment integrates over 80 scientific operations, biomedical resources and task-specific code, preserving associations among candidates, results and artifacts. From execution trajectories and outcome feedback, DrugHarness induces action hypotheses with observable applicability conditions, recommended actions and supporting evidence. An independent review agent evaluates candidate skills derived from these hypotheses through source verification and, when needed, targeted execution trials. Admitted skills guide subsequent tasks and are revised through feedback. Evaluation on MolBench and SMDD-Bench demonstrates capabilities in molecular screening, optimization and constrained design. Without evolution, DrugHarness exceeds reported MolClaw-CC results by 10.8 percentage points in affinity-comparison accuracy and 55% in mean top-three active hits on MolBench. Retrospective evaluation on skill-development tasks shows that evolution increases Qwen's affinity-comparison accuracy from 62.2% to 81.1% and optimization success from 79.5% to 87.2%. In a prospective HPK1 study, DrugHarness achieves a more favorable median docking score than Biomni among system-specific candidates. A synthesized compound achieves a cellular IC50 of 14.19 nM, a 2.64-fold potency improvement over the best input reference, with activity competitive with two selected compounds designed by experienced medicinal chemists. These results support conditional skill evolution for scientific agents and demonstrate a workflow connecting computational drug design with experimental validation.
Oct 15, 2026

Beyond Fixed Acquisition Functions: Temporal Difference Active Learning for Perturbation Discovery

Genetic and drug perturbation screens are important tools for elucidating disease mechanisms and validating therapeutic targets, but experimental costs limit the number of candidates that can be tested. Existing perturbation screening methods typically update the surrogate model with feedback while keeping the acquisition function fixed, limiting their ability to adapt selection to different response landscapes. Experimental feedback reveals current hits and informs subsequent selection by updating candidate predictions, providing a training signal for learning how to select experiments. We formulate budgeted perturbation discovery as a sequential decision problem and propose Temporal Difference Active Learning (TDAL), which learns an acquisition function online through temporal difference learning from a single screening trajectory, accounting for current hits and future discoveries. TDAL uses the Hellinger distance between hit probabilities for unmeasured candidates before and after an experiment to weight successor value, and reuses measured outcomes through leave-batch-out (LBO) to construct virtual transitions and alleviate training data scarcity. Across eight public screens spanning single, double, and triple perturbations under varied experimental configurations, TDAL achieves an average rank of 1.63 among eleven methods and ranks first on four tasks, demonstrating its adaptability across response landscapes.
Oct 14, 2026

MolHop: Scaffold-Hopping Molecular Design with Agentic Reinforcement Learning

Molecular design is often formulated as an optimization problem over existing molecular spaces. However, molecular optimization and the discovery of structurally distinct replacement molecules represent two fundamentally different search problems. LLM-based molecular design agents typically perform the former, conducting local refinement within the neighborhood of existing structures to improve target properties through structural modifications. In contrast, the latter requires exploration of a broader chemical space to discover molecules with entirely different scaffolds while preserving the functional characteristics of reference molecules. We propose MolHop, an agentic framework for cross-scaffold molecular discovery that enables models to navigate and edit within a pre-organized chemical space. MolHop organizes approximately 1.6 million molecular scaffolds from commercial molecules into a coarse-to-fine hierarchical action space. The agent selects new exploration regions through scaffold navigation actions and adjusts candidate properties through molecular editing. The framework maintains historical trajectory memory to support long-horizon search processes. On drug molecule and commercial compound tasks, connecting Grok-4.6 and DeepSeek-Flash-V4.1 to the MolHop framework substantially improves their cross-scaffold joint success rates. We develop MolHop-9B through agentic reinforcement learning, and MolHop-9B outperforms generative baselines including GPT-5.6-sol, Claude-5-Opus, and Gemini-3.1-Pro, while generating candidate molecules with larger scaffold differences from the reference molecules. These results demonstrate that effective molecular discovery beyond the traditional optimization paradigm requires structured chemical and action spaces, enabling agents to explore new structural regions rather than merely refine existing molecules.
Oct 13, 2026

PairIT: Autoregressive Transformers for Low-Data Molecule Optimization

Generating novel molecules with desired properties is a central challenge in drug discovery. Although foundational work focused on de novo generation, practical use cases require a more complex setting: conditioning on an initial seed molecule, optimizing multiple properties, and operating in data-sparse regimes. We introduce PairIT, a flexible training framework for autoregressive transformers over SMILES sequences that enables seeded generation by learning from pairs of structurally similar molecules. By leveraging matched pairs, the model learns to generate local, chemically meaningful edits that improve a property of the seed molecule. Prompt tokens extend this framework by specifying the target property, desired direction, and approximate magnitude of change. Multiple prompt tokens can be concatenated to enable multi-property optimization at inference time. For properties where pair supervision alone is insufficient, reinforcement learning post-training can further improve optimization, providing a tunable trade-off between proximity to the seed and the optimization objective. PairIT naturally supports pretraining on a large dataset and fine-tuning on a smaller dataset, which is critical for performance in data-sparse regimes. Surprisingly, we observe diminishing returns to the scale of the pretraining dataset. We demonstrate empirically on MoleculeNet and Therapeutics Data Commons datasets that, with appropriate paired-data curation, a standard transformer model of modest size (68M parameters) can achieve robust seeded molecular optimization in low-data regimes.
Oct 13, 2026

zPocket: Better Pocket Finding with Frozen Co-Folding Features

Identifying protein-ligand binding sites (pockets) is important for understanding protein function and developing drugs. However, no public method has leveraged co-folding models for novel pocket prediction; furthermore, this task lacks a suitable benchmark as existing benchmarks are within the training distribution of co-folding models. We therefore developed PocketWatch,a curated dataset of biologically relevant ligand pockets. The PocketWatch test set consists of unseen pockets stratified by sequence similarity, structural similarity, and crypticity to enable evaluation of generalization to novel and challenging pockets. Using this dataset, we develop zPocket, a method that trains pocket-prediction heads on top of frozen features from co-folding models. We show that zPocket heads outperform baseline methods across all stratifications. Our best zPocket model achieves overall per-target AUPRC of 0.745 compared to 0.598 and 0.595 for the strongest baselines, VN-EGNN and UniSite-1D retrained on the PocketWatch split (0.559 and 0.531 when using the published weights); the widely used P2Rank reaches 0.477. We further show that zPocket can be used to outperform baseline methods on top-N+2 recall of predicted pocket centroids through clustering per-residue predictions or using zPocket to rescore centroids proposed by other models. Finally, we explore two applications of zPocket: crystallographic fragment screens and a proteome-scale scan for uncharacterized pockets on human proteins. Together these results suggest that zPocket heads built on co-folding trunk features can greatly advance ligand binding site prediction.
Oct 12, 2026

MADDIE: Multi-Agent Drug Discovery Engine

Drug discovery remains a resource-intensive and time-consuming process, involving billions of dollars and a decade of development to advance a drug to market. While many in silico tools have accelerated this process, operating them still demands substantial time, effort, and expertise from medicinal chemists. Autonomous systems built on Large Language Models (LLMs) have emerged as a promising solution, yet current designs limit their performance. Existing single-agent systems scale poorly to long-horizon, multi-step, and realistic tasks, whereas multi-agent systems typically execute predefined workflows that cannot capture the iterative, non-linear nature of a real drug discovery campaign. Here, we present MADDIE, a multi-agent drug discovery engine. It comprises a central agent, Orchestrator, and four specialized worker agents: HitIdentifier, LeadOptimizer, Synthesizer, and Evaluator, each representing a critical step in a drug discovery campaign. Under Orchestrator's orchestration and coordination, these worker agents are composed into flexible workflows, enabling MADDIE to adapt its strategy and navigate the drug discovery pipeline end-to-end. Across 50 protein targets, MADDIE produces molecules satisfying key property requirements and their synthesis routes, outperforming existing agentic systems, generative models, and general-purpose LLMs by a wide margin. Our analysis reveals how these agents collaborate and that MADDIE can employ different strategies across targets to achieve the campaign's goal, while still being efficient in time and tokens. Together, they demonstrate MADDIE as a low-cost, effective, and efficient autonomous engine for accelerating drug discovery. Code and dataset is available via https://github.com/ninglab/MADDIE.
Oct 11, 2026

FragFlex: Fragment-Based Flexible Molecular Generation for Exploring Vast Chemical Space

Drug discovery requires efficient exploration of an astronomically large chemical space. Molecular graph diffusion models offer a promising approach to this task, but many require graph size to be fixed before generation. Although atom-level insertion and deletion can enable flexible-size generation, jointly modeling molecular size, atom types, and bonds while maintaining chemical validity remains challenging. We introduce FragFlex, a flexible-length discrete diffusion model that performs node insertion and deletion at the fragment level. During denoising, FragFlex jointly learns the size, fragment identities, and inter-fragment connectivity of the fragment graph. A neural attachment-site predictor and valence-aware assembler then convert the generated fragment graph into an atom-level molecule. In large-scale experiments generating 10 million molecules, FragFlex achieves near-perfect chemical validity while maintaining high uniqueness, demonstrating a strong balance between the two.
Oct 8, 2026

Cross-species representation learning aligns mouse and human neural dynamics and tracks clinical drug efficacy

Preclinical models poorly predict human drug efficacy, particularly in neurological disorders. Neural activity offers a uniquely rich source of translational information because it captures high-dimensional variation in nervous-system function that can be measured in both animals and humans. However, its high dimensionality makes it difficult to distinguish conserved disease-related features from variation arising from species, recording modality and experimental context. Here, we test whether shared neural dynamics can be identified directly from electrophysiology data by learning representations organized by biological state rather than species. We develop a dual-rule contrastive learning framework that aligns corresponding mouse and human states while preserving separation between distinct phenotypes. This framework recovered conserved sensory-response structure across species and, in epilepsy, resolved distinct relationships between three mouse models and heterogeneous human patient populations. When treated animals were projected into a frozen cross-species representation, drug-induced movement towards the human-aligned healthy state retrospectively tracked known clinical efficacy across ten model-drug combinations including a disease-specific detrimental effect. The framework also identified shared disease-associated neural dynamics between Fmr1-knockout mice and human 16p11.2 copy-number variant carriers despite differences in genetic aetiology and recording modality. Together, these findings show the potential of cross-species neural representation learning to map heterogeneous human disease onto experimentally tractable preclinical states and assess whether interventions restore human-relevant circuit function.
Oct 7, 2026

CircuitATLAS: Agentic reasoning over a systems neuroscience knowledge graph for target discovery in circuitopathies

Drug discovery for neurological disease has traditionally centered on the molecules altered by disease. But the molecules that cause pathology are not necessarily the best points from which to reverse it. Here, we ask which otherwise unaltered molecular control points can be engaged to restore pathological neural circuits toward functional states. We present CircuitATLAS, a provenance-grounded systems-neuroscience knowledge graph and agentic framework for target discovery in circuitopathies. It structures literature-derived relationships across diseases, phenotypes, electrophysiology, circuits, brain regions, cell types and molecular effectors, while deliberately excluding direct disease-gene and disease-protein edges to reduce shortcut reasoning. The graph contains 3.83 million nodes and 7.66 million edges, including 5.31 million LLM-extracted relations, and incorporates structured datasets such as the Human Cell Atlas and new multimodal in vivo measurements. We then introduce an agentic workflow that reasons from measurable disease phenotypes through their circuit and cellular substrates to molecular interventions, therapeutic feasibility and clinical constraints. Finally, we introduce a human-governed in vivo lab-in-the-loop linking hypothesis generation to experimental iteration. Within this framework an agent nominated ATP1A3, the neuronal alpha3 Na+/K+-ATPase, as a control point on cortical excitability; interneuron-restricted expression of ATP1A3 abolished the beta- and gamma-band response to a focal 4-aminopyridine challenge in vivo, and the validated target was then carried into a structure-guided small-molecule campaign terminating in a defined assay to resolve the direction of modulation. CircuitATLAS thus provides a framework for discovering therapeutics based not only on what is molecularly disrupted in disease, but on what can be controlled to restore circuit function.
Oct 7, 2026

DrugTargetWorld: A Synthetic Biobank for Training and Benchmarking AI Scientists

Drug target discovery requires distinguishing molecules that causally drive disease from those that are merely associated with it. Training and evaluating AI agents to perform this workflow end-to-end is difficult because real world biobanks lack known causal ground truth and participant-level data is access controlled. We introduce DrugTargetWorld, a framework that procedurally generates simulated biobanks, or "worlds," with known but concealed causal structure. Each world contains genotypes, proteins, health records, outcomes, and synthetic magnetic resonance imaging (MRI) for 54,000 participants. Agents must construct a disease phenotype, identify causal driver proteins, infer the beneficial direction of modulation, and optionally conduct virtual 'wet lab' experiments. We evaluated nine agents in 540 episodes across 20 cardiovascular worlds and three experimental budgets. Opus 5 and GPT-5.6 Sol achieved the highest mean composite scores, 39.98 and 35.38 of 100, respectively, and both recovered 64% of causal drivers on average. However, no agent reliably distinguished misleading non-causal proteins, and performance remained limited by the integrative judgments required to connect phenotype construction, causal evidence, and intervention decisions. By making each world's causal structure known to the evaluator but hidden from the agent, DrugTargetWorld turns end-to-end drug target discovery into a scalable training and evaluation problem with verifiable reward.
Oct 6, 2026

Information-Dense Synthesis for Molecular Discovery

Machine learning can accelerate molecular discovery by designing molecules and planning experiments. However, many scientific challenges demand molecules with very rare properties, and in this sparse setting, existing algorithms offer little gain over random guessing. We propose a method to efficiently search large regions of molecular space using algorithmically controlled stochastic synthesis. Rather than design, make and test individual molecules, we design and make complex mixtures, test them as a pool, then deconvolute the molecule-activity map. We optimize synthesis to encode maximal information. Theoretically, this approach can reduce the number of experiments required to find the optimal molecule among dd candidates from O(d)\mathcal{O}(d) to O(log⁡d)\mathcal{O}(\log d) or O(1)\mathcal{O}(1). In simulation, on estimated protein fitness landscapes, it finds active molecules with an order of magnitude fewer experiments than existing Bayesian optimization methods.
Oct 6, 2026

Can phenotypic activity be predicted without experimental readouts?

Molecular encoders contrastively pretrained on paired molecule-morphology data, such as CLOOME and CellCLIP, have been proposed as cheap surrogates for phenotypic prediction, avoiding the need to run a Cell Painting assay. We evaluate this idea under a protocol designed to control for two confounds that can inflate apparent performance: leakage across an encoder's own pretraining boundary, and the correlation between phenotypic activity and simple cytotoxicity. Testing six representations, including a non-pretrained MLP control matching CLOOME's input and layer count, on two Cell Painting screens of different scale and origin, we find that once these confounds are controlled for, CLOOME and CellCLIP show no clear advantage over plain physicochemical descriptors, also under stricter activity definitions and with non-linear probes, and that toxicity is generally easier to predict than genuine phenotypic activity across representations. The protocol is not tied to these two models, and we suggest that leakage-aware, confound-controlled evaluation should be standard practice before phenotype-pretrained encoders are trusted as surrogates for predictive phenotypic drug discovery.
Oct 5, 2026

From Benchmark to Bench: Can Agents Survive Real-World Drug Discovery?

Agentic systems increasingly coordinate molecular-design tools, but it is unclear which layer of the stack limits outcomes on real projects. We developed MAGI, an open modular agent that authors objectives, launches and monitors optimization, interprets structure--activity relationships, and revises its strategy accordingly. MAGI generates molecules either directly through the LLM or by delegating to REINVENT 4, with scoring services interchangeable behind a common contract. We tested it across nine retrospective lead-optimization campaigns from three pharmaceutical companies, replayed under fixed temporal cutoffs. Both routes produced valid structures: LLM proposals stayed closer to local chemistry and reached comparable or higher primary activity in fewer operations, whereas REINVENT explored broader chemical space. Whether a campaign met its objective depended on the predictive models, not on the generation route: attainment followed model accuracy on the chemistry proposed, dropping once that chemistry moved outside the model's applicability domain. Separately, a blinded evaluation asked whether the MAGI's output could pass as expert work: chemists were not able to discriminate agentic proposals from held-out compounds, and judged the SAR reasoning broadly plausible yet incomplete. Together, these results position MAGI as a coordination layer pluggable into existing computational chemistry workflows. The ceiling on real projects, however, remains currently set by scorer applicability rather than by tool orchestration.